Is Buying Vanda Pharmaceuticals Inc. (VNDA) Here a Winning Strategy?

February 15, 2018 - By Louis Casey

Investors sentiment increased to 1.43 in Q3 2017. Its up 0.26, from 1.17 in 2017Q2. It is positive, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 21 funds opened positions while 45 raised stakes. 38.89 million shares or 4.39% more from 37.25 million shares in 2017Q2 were reported.
1.65 million were accumulated by State Street Corp. Morgan Stanley reported 1.08 million shares stake. Sei Co accumulated 0.02% or 267,671 shares. Birchview Cap Lp has invested 0.63% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Rothschild Asset Inc invested in 1.31 million shares or 0.26% of the stock. North Star Inv Management Corporation accumulated 5,000 shares or 0.01% of the stock. The California-based Schwab Charles Management has invested 0.01% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Prudential Fincl reported 588,978 shares. Tiaa Cref Investment Mngmt Ltd Liability Company has 424,887 shares for 0.01% of their portfolio. Art Advisors Ltd Liability Com invested in 59,900 shares or 0.05% of the stock. Point72 Asia (Hong Kong) Limited holds 59 shares or 0% of its portfolio. Ameritas Invest Partners has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). University Of Notre Dame Du Lac has invested 0.79% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Moreover, One Association has 0.02% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 18,890 shares. Geode Cap Management Lc has 426,044 shares.

Since January 2, 2018, it had 0 insider buys, and 4 selling transactions for $3.36 million activity. 10,367 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares with value of $157,565 were sold by Gulino Richard L.. 191,760 shares were sold by Polymeropoulos Mihael Hristos, worth $2.93M. Kelly James Patrick sold $140,494 worth of stock or 9,155 shares.

The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a huge mover today! The stock increased 5.99% or $0.95 during the last trading session, reaching $16.8. About 314,252 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since February 15, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.
The move comes after 5 months positive chart setup for the $754.78M company. It was reported on Feb, 15 by Barchart.com. We have $17.30 PT which if reached, will make NASDAQ:VNDA worth $22.64 million more.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on February, 21. They expect $-0.12 earnings per share, down 400.00 % or $0.16 from last year’s $0.04 per share. After $-0.10 actual earnings per share reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 22 analyst reports since September 2, 2015 according to SRatingsIntel. Jefferies maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Monday, June 26. Jefferies has “Buy” rating and $2100 target. The rating was maintained by Piper Jaffray with “Buy” on Thursday, August 3. The firm has “Buy” rating given on Monday, January 8 by Oppenheimer. The firm has “Buy” rating by Jefferies given on Tuesday, February 13. The rating was initiated by Brean Capital on Wednesday, October 21 with “Buy”. Aegis Capital initiated it with “Buy” rating and $24 target in Wednesday, November 9 report. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The firm earned “Outperform” rating on Monday, October 30 by Oppenheimer. The firm has “Buy” rating given on Thursday, August 3 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, September 2 by Piper Jaffray.

More recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Marketwatch.com which released: “Vanda Pharma shares decline as goal of itch drug study not reached” on September 13, 2017. Also Seekingalpha.com published the news titled: “Vanda Pharmaceuticals’ (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results …” on November 08, 2017. Prnewswire.com‘s news article titled: “Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial …” with publication date: February 14, 2018 was also an interesting one.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $754.78 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: